# Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

> **NCT01087554** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 249 (estimated)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Vorinostat
- **DRUG:** Everolimus
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT01087554
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2010-03
- **Primary completion:** 2026-08-18
- **Final completion:** 2026-08-18
- **Target enrollment:** 249 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01087554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01087554, "Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01087554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*